Founded in 2005, Eusol Biotech Co., Ltd. is committed to developing new drugs for unmet medical need and has been focusing on the drug treatment of nerve injuries for many years. The investigational growth factor protein drug ES135 has gone through several phase I, II clinical studies and entered the phase 3 clinical trial of spinal cord injury in 2018. The research findings have been published progressively. Given the lengthy process and substantial investment required for new drug development, along with the growing medical needs driven by an aging society, Eusol has adjusted its business model in 2022 and shifted from in-house PIC/S GMP manufacturing facility to out-sourced production. Meanwhile, we are collaborating with other pharmaceutical companies to co-develop niche generics with specialized formulations and actively bring in drugs to support domestic healthcare demands and accelerate our business transformation.